Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, fastact-2 study of intercalated erlotinib with first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC)
T. Mok
Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, fastact-2 study of intercalated erlotinib with first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC)
T. Mok